Wow_老虎社区_美港股上老虎

belle111
2021-05-03

Wow

Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal

(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm

Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":108561796,"tweetId":"108561796","gmtCreate":1620042508015,"gmtModify":1634208312317,"author":{"id":3576012921296307,"authorId":3576012921296307,"authorIdStr":"3576012921296307","name":"belle111","avatar":"https://static.tigerbbs.com/6f46e52365860eac5a81ef82845a2f73","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/108561796","repostId":1106857820,"repostType":4,"repost":{"id":"1106857820","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620041381,"share":"https://www.laohu8.com/m/news/1106857820?lang=&edition=full","pubTime":"2021-05-03 19:29","market":"us","language":"en","title":"Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1106857820","media":"Reuters","summary":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm","content":"<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech firm Roivant Sciences to go public via $7.3 billion SPAC deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech firm Roivant Sciences to go public via $7.3 billion SPAC deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-03 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR &amp; Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.</p><p>The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.</p><p>Investors including Fidelity Management &amp; Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.</p><p>After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.</p><p>SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106857820","content_text":"(Reuters) -Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp, backed by former KKR & Co dealmaker Jim Momtazee, in a deal that values the biotech company at $7.3 billion.The deal is expected to deliver up to $611 million of gross proceeds to fund Roivant’s discovery and development programs.Investors including Fidelity Management & Research and SB Management, a subsidiary of SoftBank Group Corp have agreed to invest $200 million in the deal.After the deal closes in the third quarter this year, the biotech firm will list on the Nasdaq under the ticker symbol “ROIV”.SPACs are shell companies that raise funds through an initial public offering to take a private company public through a merger at a later date.","news_type":1},"isVote":1,"tweetType":1,"viewCount":219,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}